Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

the 31 patients with stable disease or better, one

patient had a complete response and four patients had partial

responses (two unconfirmed).

-- SNS-595 has been generally well tolerated in this trial, with a low

rate of febrile neutropenia or other Grade 3/4 adverse events and

manageable Grade 1/2 nausea or vomiting. Based on the drug's

observed safety profile and indications of clinical activity,

Sunesis amended the protocol to explore a higher dose of SNS-595 in

this trial. Enrollment has begun at a dose of 60 mg/m2 over twenty-

eight days, and Sunesis anticipates enrolling approximately 30

patients at this dose in the third quarter of this year.

-- Data from this trial has been accepted for presentation at the 44th

ASCO Annual Meeting.

-- Sunesis updated the results from the company's Phase 1 clinical trial

of single-agent SNS-595 in patients with relapsed or refractory acute

leukemias, which had previously been reported at the 49th Annual

Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia

in December 2007. Since the ASH presentation, an additional patient in

this trial has achieved a complete remission.

-- Twelve of 30 patients (43 percent) who received doses of SNS-595 of

50 mg/m2 or greater on a weekly dose schedule have now achieved bone

marrow blast reductions to less than five percent, and five of these

12 patients achieved either complete remission, complete remission

without platelet recovery or complete remission with incomplete

recovery of normal hematopoietic blood elements.

-- SNS-595 was generally well tolerated in this trial, with a

dose-limiting toxicity of reversible Grade 3/4 oral mucositis.

-- Based on these promising results, Sunesis
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014  Having the right people ... vital to accelerating business growth and achieving clinical and ... Association (AHA) Leadership Summit, July 20-22, 2014, in ... of hospital executives and healthcare experts discussing how partnerships ... Carrocino , President & Chief Executive Officer of Cape ...
(Date:7/23/2014)... MOINES, Iowa (PRWEB) July 23, 2014 ... join the business as vice president of Agricultural Biotechnology ... Mendel Biotechnology where he served most recently as president, ... extensive biotechnology and business leadership in the seed and ... Pioneer,” said Paul E. Schickler , president of ...
(Date:7/23/2014)... , July 23, 2014  GrowBLOX Sciences, Inc. (OTCQB: GBLX), ... it is filing for two medical marijuana dispensary locations in ... in addition to the Clark County, Nevada ... use permit, as previously announced.  GrowBLOX Sciences, CEO ... submitting two new applications for dispensaries in the ...
(Date:7/23/2014)... N.J. (PRWEB) July 23, 2014 ... Comprehensive Cancer Center has joined its Strategic Alliance ... Strategic Alliance Partnership program, UNC Lineberger will have ... to raise awareness of its cutting-edge research initiatives, ... from UNC Lineberger will work with OncLive to ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
... , ... responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s allogeneic adult ... the FDA in the United States. , ... (PRWEB) June 24, 2010 -- Stemedica Cell Technologies, Inc., ...
... Reportlinker.com announces that a new market research report is available in its catalogue: ... Global Nucleic Acid Testing Industry , ... http://www.reportlinker.com/p0209257/Global-Nucleic-Acid-Testing-Industry.html , , , ... market for Nucleic Acid Testing in US$ Million. Annual estimates and forecasts are provided for ...
... ... ... DuPont biofuels collaborations received top honors in the 2010 “Transformative Technologies 30” survey, conducted ... and the DuPont partnership with Bio Architecture Lab ( BAL ) to develop macroalgae ...
Cached Biology Technology:Stemedica Announces the Appointment of Dr. Csar Amescua Garcia as Medical and Regulatory Affairs Director – Latin America 2Reportlinker Adds Global Nucleic Acid Testing Industry 2Reportlinker Adds Global Nucleic Acid Testing Industry 3Reportlinker Adds Global Nucleic Acid Testing Industry 4Reportlinker Adds Global Nucleic Acid Testing Industry 5Reportlinker Adds Global Nucleic Acid Testing Industry 6Reportlinker Adds Global Nucleic Acid Testing Industry 7Reportlinker Adds Global Nucleic Acid Testing Industry 8Reportlinker Adds Global Nucleic Acid Testing Industry 9Reportlinker Adds Global Nucleic Acid Testing Industry 10DuPont Named to Biofuels Digest 2010 “Transformative Technologies 303 2DuPont Named to Biofuels Digest 2010 “Transformative Technologies 303 3DuPont Named to Biofuels Digest 2010 “Transformative Technologies 303 4
(Date:7/23/2014)... 2015, Springer will publish the International Journal of ... of the Taiwan Fuzzy Systems Association (TFSA). The cooperation ... in the area of fuzzy research., The International ... high-quality papers that deal with the theory, design and ... and extension theory systems ranging from hardware to software. ...
(Date:7/23/2014)... , one of the principal bacteria that cause ... genetic material over time, possibly coinciding with dietary ... This is highlighted in a study by researchers ... the Laboratorio Nacional de Genmica para la Biodiversidad ... who, for the first time, have sequenced genetic ...
(Date:7/23/2014)... equipment, trained personnel, and detection dogs to safeguard ... A revolutionary new electronic chip with nano-sized chemical ... easier. , The groundbreaking nanotechnology-inspired sensor, devised by ... School of Chemistry and Center for Nanoscience and ... picks up the scent of explosives molecules better ...
Breaking Biology News(10 mins):Ancient genetic material from caries bacterium obtained for the first time 2Nano-sized chip "sniffs out" explosives far better than trained dogs 2
... of 10 new cancer drugs successfully clear preclinical ... clinical testing. A new partnership facilitated by SAIC-Frederick ... The partnership brings together The UC Davis Cancer ... Institute,s (NCI) Center for Advanced Preclinical Research (CAPR), ...
... from Germany, Malaysia, Vietnam, the Philippines, the UK, Bulgaria ... LEGATO, which will be launched on June 14, 2011, ... and Ecological Engineering Assessment Tools for risks and ... to advance long-term sustainable development of irrigated rice fields, ...
... huge plume of sulphur dioxide that spewed from Chile,s Puyehue-Cordn ... km south of Santiago. After lying dormant for more ... beginnings of this major volcanic eruption. On 4 June, a ... gas over 10 km high. ,Several thousand people were evacuated ...
Cached Biology News:NCI partners with Jackson Laboratory, UC Davis to speed cancer clinical trials 2NCI partners with Jackson Laboratory, UC Davis to speed cancer clinical trials 3LEGATO -- a major international project on sustainable development of rice ecosystems in Southeast Asia 2
Control primers and template for 5kb and 15 kb products....
Carrier Serum...
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: